Erlotinib for the Treatment of Non-Small Cell Lung Cancer Technology Appraisal

May 2019

Cancer

Country of origin: UK

Erlotinib is recommended as an alternative to docetaxel for patients with non-small-cell lung cancer (NSCLC) who have already tried one chemotherapy regimen but it has not worked. Erlotinib should be used only when the manufacturer provides the drug at the same overall treatment cost as docetaxel. This cost includes the cost of giving the drug, treatments for any side effects and the cost of monitoring patients to check that treatment is working.

If the overall treatment cost is equal, specialists should discuss with patients the potential benefits and risks of erlotinib and docetaxel before deciding which treatment to use.

Erlotinib is not recommended for people with locally advanced or metastatic NSCLC who cannot take docetaxel and have already tried one chemotherapy regimen but it has not worked.

Erlotinib is not recommended for people who have already tried two chemotherapy regimens, including docetaxel, but they haven't worked.

Healthcare professionals should not stop prescribing erlotinib for people who were already taking it when the guidance was issued. These patients should be able to carry on taking erlotinib until they and their specialist decide that it is the right time to stop treatment.

'Lung cancer (non-small-cell) - erlotinib: guidance ' is available online.

Resources

Reassessing Carcinogenic HPV Types May 2019 Virtually all cases of cervical cancer are caused by persistent infections with a restricted set of human papillomaviruses...
Sebaceous Carcinoma Of The Skin Of The Breast: Case Report May 2019 Sebaceous gland tumours are rare and their presence should be considered as a marker for Muir-Torre Syndrome, alerting to...
Cervical screening website May 2019 The British Society for Colposcopy and Cervical Pathology (BSCCP) has a website able to send online mail shots and provide...
Report on deaths from head and neck cancers in England April 2019 Public Health England’s National End of Life Care Intelligence Network has published a new report examining who dies from...
1 in 5 people get skin cancer April 2019 Skin cancer is one of the most common forms of cancer and can appear anywhere on the skin. Non-melanoma skin cancers, like...
Online Tool for Calculating Colorectal Cancer Risk April 2019 An online tool for calculating colorectal cancer risk in men and women age 50 or older was launched recently, based on a...
The Lancet March 2019 The Lancet

Available for both iPad & iPhone, the new and improved The Lancet app is free to download and offers...
Keeping Up To Date March 2019 The late diagnosis of almost all types of cancer usually means the disease has already spread within the body, making it...
inPractice® Oncology. March 2019 inPractice® Oncology is the only point-of-care clinical reference designed to meet the unique needs of specialists. Full...
Researchers in bowel cancer discovery February 2019 Scientists have discovered how genes cause bowel cancer cells to become resistant to treatments used against the disease....
Search by Keyword